The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Pulmonary Or Respiratory Drug Delivery Market From 2026 To 2030?
The pulmonary or respiratory drug delivery market has experienced substantial expansion in recent years. Its valuation is projected to increase from $75.67 billion in 2025 to $82.23 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. This historical growth can be ascribed to an increase in the prevalence of asthma and COPD, the widespread use of inhalers, the proliferation of respiratory hospitals, enhancements in aerosol technologies, and the expansion of homecare treatments.
The pulmonary or respiratory drug delivery market is anticipated to show significant expansion over the next few years, with its size projected to reach $114.23 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.6%. This rise during the forecast period is attributed to an aging population, increased exposure to air pollution, the development of digital inhalers, the broadening of homecare settings, and a surge in chronic respiratory conditions. Noteworthy trends for this period include a heightened adoption of inhalation-based drug delivery, an increasing demand for respiratory therapies at home, the wider application of dry powder and metered dose inhalers, an expansion of chronic respiratory disease management strategies, and an intensified focus on user-friendly delivery devices.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
What Key Drivers Are Influencing The Growth Of The Pulmonary Or Respiratory Drug Delivery Market?
The rising occurrence of pneumonia is projected to stimulate the expansion of the pulmonary or respiratory drug delivery market moving forward. Pneumonia, a lung infection, involves the inflammation of air sacs, which may become filled with fluid or pus, leading to symptoms like a cough, fever, and difficulty breathing. The increasing prevalence of pneumonia is attributed to factors such as aging populations, weakened immune systems, respiratory infections, air pollution, smoking, and the rise of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery assists pneumonia patients by delivering medications, including antibiotics, bronchodilators, or anti-inflammatory agents, directly to the lungs. This enables more rapid and effective treatment to alleviate symptoms, reduce inflammation, clear infections, and improve respiratory function, ultimately enhancing recovery and preventing complications. For instance, in December 2024, as per Clinical Trials Arena, a UK-based clinical research news platform, hospital admissions for Mycoplasma pneumoniae saw a 461% increase from October 2023 to February 2024, climbing from 110 to 617 admissions. Furthermore, 20.2% of pneumonia cases were detected in children aged 0 to 4 years, 25.4% in children aged 5 to 9 years, and 17.5% in children aged 10 to 14 years, contributing 410 of the 650 reported cases. Therefore, the growing prevalence of pneumonia is a driving force behind the pulmonary or respiratory drug delivery market.
Which Segments Are Included In The Analysis Of The Pulmonary Or Respiratory Drug Delivery Market?
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
Which Trends Are Impacting The Growth Of The Pulmonary Or Respiratory Drug Delivery Market?
Leading companies in the pulmonary or respiratory drug delivery market are increasingly focusing on technological breakthroughs like complex drug delivery systems, which improve treatment effectiveness and patient adherence. These sophisticated systems are advanced technologies that enhance the targeted delivery and controlled release of therapeutic agents, thereby boosting drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company manufacturing generic and branded medicines, along with Kindeva Drug Delivery L.P., a US-based company offering drug delivery solutions, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, an inhalation aerosol approved by the Food and Drug Administration, a US-based government agency. This product represents the first generic version of AstraZeneca’s Symbicort and is a metered-dose inhaler that combines budesonide and formoterol for treating asthma and chronic obstructive pulmonary disease. It comes in two strengths: 80 micrograms and 160 micrograms, both with 4.5 micrograms of formoterol.
Which Key Industry Participants Are Active In The Pulmonary Or Respiratory Drug Delivery Market?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
Read the full pulmonary or respiratory drug delivery market report here:
Which Region Is Expected To Register The Fastest Growth In The Pulmonary Or Respiratory Drug Delivery Market?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pulmonary Or Respiratory Drug Delivery Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp
Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2026, By The Business Research Company
Pulmonary Drug Delivery Devices Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Respiratory Disease Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model